| BD BBL Sensi Disc Cefotaxime - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231606 and 231607;
5 ug, Catalog…Z-1020-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Cefpodoxime - 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231673 and 231674Z-1021-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ceftaroline - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 232231Z-1022-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ceftazidime- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231632and 231633Z-1023-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ceftriaxone- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231634 and 231635Z-1024-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Cefuroxime- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231621Z-1025-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Chloramphenicol- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 230733and 231274Z-1026-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ciprofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231657and 231658Z-1027-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Clarithromycin- 15 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231678Z-1028-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Doripenem- 15 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 232219Z-1029-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ertapenem- 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 232174 and 232175Z-1030-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Imipenem- 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231644 and 231645Z-1031-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Levofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231705 and 231706Z-1032-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Meropenem- 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231703 and 231704Z-1033-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Minocycline - 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231250 and 231251Z-1034-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Moxifloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231758Z-1035-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Ofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231672Z-1036-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Piperacillin/Tazobactam- 100/10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231691 and 2316…Z-1037-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231541 and 231544Z-1038-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Sulfamethoxazole with Trimethoprim 23.75/1.25 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 23…Z-1039-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| BD BBL Sensi Disc Tetracycline 30 ug,used for semi-quantitative in vitro susceptibility testing. Catalog Number 230998 and 231344Z-1040-2024 · JTN | Becton Dickinson & Co. | Recall | Feb 8, 2024FDA classification date |
| Thermo Scientific Oxoid Sulbactam/Durlobactam Disc (10/10 µg) SUD20K232276 · JTN | Oxoid Limited (Part of Thermo Fisher Scientific) | 510(k) | Oct 6, 2023FDA decision date |
| HardyDisk AST Sulbactam/Durlobactam 10/10µg (SUD20)K231568 · JTN | Hardy Diagnostics | 510(k) | Jul 6, 2023FDA decision date |
| BD BBL Sensi-Disc Lefamulin 20µg (LMU-20)K230651 · JTN | Becton, Dickinson and Company | 510(k) | Jun 7, 2023FDA decision date |
| HardyDisk AST Rezafungin 5µg (RZF5)K230827 · JTN | Hardy Diagnostics | 510(k) | Jun 1, 2023FDA decision date |